<?xml version="1.0" encoding="UTF-8"?>
<ref id="B84">
 <label>84.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Palatnik-de-Sousa</surname>
    <given-names>CB</given-names>
   </name>
   <name>
    <surname>Barbosa A de</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Oliveira</surname>
    <given-names>SM</given-names>
   </name>
   <name>
    <surname>Nico</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Bernardo</surname>
    <given-names>RR</given-names>
   </name>
   <name>
    <surname>Santos</surname>
    <given-names>WR</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine</article-title>. 
  <source>Expert Rev Vaccines</source>. (
  <year>2008</year>) 
  <volume>7</volume>:
  <fpage>833</fpage>â€“
  <lpage>51</lpage>. 
  <pub-id pub-id-type="doi">10.1586/14760584.7.6.833</pub-id>
  <?supplied-pmid 18665780?>
  <pub-id pub-id-type="pmid">18665780</pub-id>
 </mixed-citation>
</ref>
